NCT01555008View on ClinicalTrials.gov

Study to Evaluate the Pharmacodynamic and Pharmacokinetic Effects of LX4211 in Subjects With Type 2 Diabetes and Renal Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

August 31, 2013

Conditions
Type 2 Diabetes MellitusRenal Impairment
Interventions
DRUG

LX4211

Subjects will receive LX4211 once daily for 7 days

DRUG

LX4211 Placebo

Subjects will receive LX4211 placebo once daily for 7 days

Trial Locations (6)

32132

Lexicon Investigational Site, Edgewater

36207

Lexicon Investigational Site, Anniston

55404

Lexicon Investigational Site, Minneapolis

78209

Lexicon Investigational Site, San Antonio

91911

Lexicon Investigational Site, Chula Vista

98057

Lexicon Investigational Site, Renton

Sponsors
All Listed Sponsors
lead

Lexicon Pharmaceuticals

INDUSTRY